Biliary Tract Cancer Pipeline Insight Landscape 2021 - ResearchAndMarkets.com

The "Biliary Tract Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This Biliary Tract Cancer - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Biliary Tract Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Biliary Tract Cancer.

Biliary Tract Cancer Emerging Drugs Chapters

This segment of the Biliary Tract Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Biliary Tract Cancer Emerging Drugs

Pembrolizumab: Merck & Co.

Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Biliary Tract Cancers.

Disitamab vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells. Currently, it is in Phase II stage of clinical trial evaluation to treat Biliary Tract Cancers.

Major Players in Biliary Tract Cancer

There are approx. 50+ key companies which are developing the therapies for Biliary Tract Cancer. The companies which have their Biliary Tract Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Key Questions Answered

• How many companies are developing Biliary Tract Cancer drugs?
• How many Biliary Tract Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Biliary Tract Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Biliary Tract Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Biliary Tract Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck
• RemeGen
• EMD Serono
• SMT bio Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Jiangsu HengRui Medicine Co., Ltd.
• InnoPharmax Inc.
• Lee's Pharmaceutical Limited
• Hoffmann-La Roche
• Eisai
• TerSera Therapeutics LLC
• Shanghai Miracogen Inc.
• Zymeworks Inc.
• Mirati Therapeutics
• BeiGene
• Bristol-Myers Squibb
• Eli Lilly and Company
• Ipsen
• Threshold Pharmaceuticals
• Leap Therapeutics
• Hutchison Medipharma Limited
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Daiichi Sankyo
• 3D Medicines
• RaND Biosciences
• Incyte Corporation
• Sotio a.s.
• Carisma Therapeutics Inc
• Senhwa Biosciences, Inc.
• Seagen
• Bolt Biotherapeutics, Inc.
• Black Diamond Therapeutics, Inc.
• Redx Pharma Plc
• Silverback Therapeutics
• Taiho Oncology, Inc.
• Zai Lab (Shanghai) Co., Ltd.

Key Products

• Pembrolizumab
• Disitamab vedotin
• Bintrafusp alfa
• SMT-NK
• HA121-28
• SHR1258
• D07001
• ZKAB001
• Atezolizumab
• Lenvatinib
• telotristat ethyl
• MRG003
• ZW25
• Sitravatinib
• Tislelizumab
• Nivolumab
• Ramucirumab
• Nanoliposomal Irinotecan
• TH-302
• DKN-01
• Surufatinib
• TQB2450
• Trastuzumab deruxtecan
• Envafolimab
• SC-43
• INCB001158
• SO-C101
• CT-0508
• CX-4945
• Tucatinib
• BDC-1001
• BDTX-189
• RXC004
• SBT6050
• TAS0728
• Niraparib

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/4xcg55

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005785/en/